Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises th

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a B

Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 mill

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the pr

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Es

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst co

ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter

Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Cal

ADAR1 Capital Management LLC raised its holdings in Urogen Pharma (NASDAQ: URGN) by 139.1% during th

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the pr

UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZU

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing inno

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, to

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical a

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's fi

10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $

5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weight

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tr

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's int

PRINCETON, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnol

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent B

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

  On Wednesday, 215 companies set new 52-week lows.

  On Monday, 198 companies reached new 52-week lows.

  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly

    During Tuesday's trading, 505 companies set new 52-week lows.

    On Friday, 313 companies hit new 52-week lows.

    On Thursday, 147 companies achieved new lows for the year.